Skip to main content
Journal cover image

Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

Publication ,  Journal Article
Mendoza, P; Gruell, H; Nogueira, L; Pai, JA; Butler, AL; Millard, K; Lehmann, C; Suárez, I; Oliveira, TY; Lorenzi, JCC; Cohen, YZ; Wyen, C ...
Published in: Nature
September 2018

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption. Participants received three infusions of 30 mg kg-1 of each antibody at 0, 3 and 6 weeks. Infusions of the two antibodies were generally well-tolerated. The nine enrolled individuals with antibody-sensitive latent viral reservoirs maintained suppression for between 15 and more than 30 weeks (median of 21 weeks), and none developed viruses that were resistant to both antibodies. We conclude that the combination of the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 can maintain long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

September 2018

Volume

561

Issue

7724

Start / End Page

479 / 484

Location

England

Related Subject Headings

  • Young Adult
  • Virus Latency
  • Virus Activation
  • Viremia
  • Phylogeny
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Historically Controlled Study
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K., … Nussenzweig, M. C. (2018). Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 561(7724), 479–484. https://doi.org/10.1038/s41586-018-0531-2
Mendoza, Pilar, Henning Gruell, Lilian Nogueira, Joy A. Pai, Allison L. Butler, Katrina Millard, Clara Lehmann, et al. “Combination therapy with anti-HIV-1 antibodies maintains viral suppression.Nature 561, no. 7724 (September 2018): 479–84. https://doi.org/10.1038/s41586-018-0531-2.
Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 Sep;561(7724):479–84.
Mendoza, Pilar, et al. “Combination therapy with anti-HIV-1 antibodies maintains viral suppression.Nature, vol. 561, no. 7724, Sept. 2018, pp. 479–84. Pubmed, doi:10.1038/s41586-018-0531-2.
Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC, Cohen YZ, Wyen C, Kümmerle T, Karagounis T, Lu C-L, Handl L, Unson-O’Brien C, Patel R, Ruping C, Schlotz M, Witmer-Pack M, Shimeliovich I, Kremer G, Thomas E, Seaton KE, Horowitz J, West AP, Bjorkman PJ, Tomaras GD, Gulick RM, Pfeifer N, Fätkenheuer G, Seaman MS, Klein F, Caskey M, Nussenzweig MC. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 Sep;561(7724):479–484.
Journal cover image

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

September 2018

Volume

561

Issue

7724

Start / End Page

479 / 484

Location

England

Related Subject Headings

  • Young Adult
  • Virus Latency
  • Virus Activation
  • Viremia
  • Phylogeny
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Historically Controlled Study